N/A N=28 Ankle-foot Orthoses for Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in WIQ Distance Subscore — 22.7; -7.2 Scale units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=840 Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Peripheral Arterial Occlusive Disease
Primary: Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment — 49; 43; 27; 30 participants — p=0.2587
N/A N=604 Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes
Diabetic Foot · Peripheral Arterial Disease · Diabetic Foot Ulcer
Primary: Diagnostic Accuracy — 36; 42; 55; 41 percentage
Phase 2 N=174 A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
Acute Peripheral Arterial Occlusion
Primary: The Proportion of Subjects With >50% Thrombolysis — 43.8; 47.4; 81.0; 47.4 percentage of participants
N/A N=1,455 Prevention of Ischemic Events in Patients With Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Incidence of Major Cardiovascular Events — 112; 47; 51; 17 participants — p=<0.001
N/A N=10 Improving Walking in Peripheral Artery Disease
Peripheral Artery Disease
Primary: Changes in Walking Distance After Three-months Intervention — 289.68; 262.95 meters
N/A N=33 Improving Mobility in Peripheral Artery Disease Using an Ankle Foot Orthosis
Peripheral Artery Disease
Primary: Maximum Walking Time From the Gardner Graded Treadmill Protocol — 117.7; 197.5; 188; 339.9 Seconds
Phase 3 N=76 ARREST PAD (Peripheral Arterial Disease)
Arterial Occlusive Disease · Intermittent Claudication · Insulin Resistance
Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min
N/A N=85 Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery
Peripheral Arterial Occlusion or Emboli
Primary: Angiographic Assessment of Vessel Patency at Immediate Post-procedure as Measured by TIMI Scores — 74 Participants
Phase 2 N=20 Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia
Critical Limb Ischemia
Primary: Reintervention, Above Ankle Amputation and Restenosis (RAS) — 7; 4 Participants
Phase 4 N=102 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Peripheral Arterial Disease
Primary: Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic…
Phase 2 N=203 Edoxaban in Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Percentage of Participants With Clinically Relevant Bleeding During Treatment — 8; 11; 6; 6 percentage of participants
N/A N=358 Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia
Critical Lower Limb Ischemia
Primary: Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA) — 0.605; 0.616 mm
N/A N=85 Comprehensive Magnetic Resonance of Peripheral Arterial Disease
Peripheral Artery Disease
Primary: Plaque Volume — 10.5; 10.5; 10.8 cm^3 — p=0.32
N/A N=35 Exercise Rehabilitation in Veterans With PAD
Peripheral Arterial Disease · Intermittent Claudication
Primary: Modified Physical Performance Test — 31.8; 32.3 scores on a scale
N/A N=238 Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease
Peripheral Artery Disease · Amputation · Smoking
Primary: Positive Predictive Value of Digital ABI in Diagnosing PAD — 8; 2 Participants
N/A N=20 Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Device Technical Success — 29 lesions
N/A N=60 Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)
Popliteal Artery Aneurysm
Primary: Number of Subjects With Primary Patency at 12 Months — 40; 11 Participants
N/A N=347 Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics.
Peripheral Arterial Disease
Primary: Effect of an Exercise Intervention on Walking Ability (Functional Outcome) — 301.4; 185.1 meters
N/A N=67 Safety and Efficacy Study of a New Intermittent Pneumatic Compression Device to Treat Patients With Peripheral Arterial Disease (PAD) Stage II
Peripheral Arterial Disease
Primary: Absolute Claudication Distance (ACD) — 54.374; 0.792 Meters
N/A N=121 Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization
Peripheral Artery Disease
Primary: Safety Endpoint: Number of Participants With Freedom From Major Adverse Events — 110 Participants
Phase 3 N=159 Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
Peripheral Arterial Disease
Primary: Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb…
N/A N=25 Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal
Peripheral Artery Disease · PAD · Claudication
Primary: Rate of Clinically Driven Target Lesion Revascularization (TLR) — 4.0; 8.2 % probablity of clinically driven TLR
Phase 2 N=67 ACP-01 in Patients With Critical Limb Ischemia
Critical Limb Ischemia
Primary: Wound Size, Amputation or Survival — 12; 3 participants — p=0.258
N/A N=172 The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions
Peripheral Artery Disease
Primary: Major Adverse Events (MAEs) Within 30 Days — 2 Participants
Phase 3 N=6,564 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Peripheral Artery Disease
Primary: Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major…
N/A N=797 Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT)
Peripheral Arterial Disease · Quality of Life · Quality of Care
Primary: Peripheral Artery Disease (PAD) - Specific Health Status — 70.7; 66.9 units on a scale of 0-100
N/A N=14 Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
Peripheral Arterial Disease · Peripheral Artery Disease
Primary: Endothelial Function — 6.13; 3.78 % dilation
Phase 2 N=119 Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
Peripheral Arterial Disease (PAD)
Primary: Segment-level Sensitivity and Specificity of VE-MRI at 3 Ferumoxytol Dosing Levels and Differences in Sensitivity and Specificity by Dose Group — 71.8; 76.8; 81.8; 71.2…
N/A N=28 Percutaneous Deep Vein Arterialization Post-Market Study
Critical Limb Ischemia
Primary: Amputation-free Survival — 67.2 percentage of participants